Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
ShangPharma Mulls Going Private Again
by Jean-François Tremblay
July 16, 2012
| A version of this story appeared in
Volume 90, Issue 29
Less than two years after its initial public stock offering, the Chinese contract research firm ShangPharma may delist from the New York Stock Exchange after two major shareholders offered to buy all of the shares they do not already own. CEO and founder Michael Xin Hui, who owns 54% of ShangPharma, and the private equity firm TPG Star Charisma, with an 11% stake, made an offer to buy all additional shares for as much as $9.50 each. Prior to their offer, shares in ShangPharma traded for about $7.00, less than half of their $15 listing price in October 2010. ShangPharma’s board says it will review the offer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X